

Supplementary Table 1. Factors related to recurrence-free survival after stereotactic body radiation therapy

| | Univariate analysis | | Multivariate analysis | |
|-------------------------------------|---------------------|---------|-----------------------|---------|
| | HR (95% CI) | P-value | HR (95% CI) | P-value |
| Sex, female | 1.891 (0.733–4.876) | 0.188 | | |
| Age | 1.004 (0.969–1.040) | 0.845 | | |
| Etiology, non-HBV* | 1.644 (0.682–3.966) | 0.268 | | |
| Albumin | 0.581 (0.236–1.431) | 0.238 | | |
| Bilirubin | 1.113 (0.484–2.560) | 0.801 | | |
| Tumor size | 2.494 (1.499–4.149) | <0.001 | 2.791 (1.604–4.858) | <0.001 |
| Tumor number, multiple [†] | 0.587 (0.263–1.311) | 0.194 | | |
| Alpha-fetoprotein | 1.000 (0.999–1.001) | 0.727 | | |
| PIVKA-II | 1.001 (0.996–1.005) | 0.832 | | |
| No. of prior treatment session | 1.212 (1.055–1.392) | 0.007 | 1.199 (1.044–1.378) | 0.010 |

Values in the parentheses were set as the reference.

HR, hazard ratio; CI, confidence interval; HBV, hepatitis B virus; PIVKA, protein induced by vitamin K absence or antagonist.

*Categorical variables are divided as HBV (+) vs. HBV (-).

[†]Categorical variables are divided as single vs. multiple.